Mounjaro and Pancreatitis: The Biology of Why Tirzepatide May Inflame the Pancreas

What the Mounjaro label actually says

Section 5.2 of the Mounjaro prescribing information states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or with Mounjaro [1]. It tells prescribers to observe patients for signs and symptoms after starting the drug: persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, the label says to discontinue Mounjaro and initiate appropriate management [1]. Acute pancreatitis also appears in the label's list of serious adverse reactions [1].

Does tirzepatide actually increase pancreatitis risk in the trials?

A 2023 systematic review and meta-analysis pooled nine randomized trials of tirzepatide in type 2 diabetes and obesity: 6,828 people on tirzepatide and 3,043 controls on placebo, basal insulin or a selective GLP-1 receptor agonist. Pancreatitis was not significantly more common with tirzepatide, with a risk ratio of 1.46 and a 95% CI of 0.59 to 3.61, and no heterogeneity between trials [4].

For GLP-1 receptor agonists as a class, a 2017 meta-analysis of three long-term placebo-controlled trials covering 9,347 drug-treated and 9,353 placebo-treated patients found no increase in acute pancreatitis (Peto odds ratio 0.745, 95% CI 0.47 to 1.17) [6]. A 2025 meta-analysis of 21 trials and 99,599 patients found more gastrointestinal and gallbladder events with GLP-1 receptor agonists but no difference in pancreatitis [7]. A 2025 review of real-world data on liraglutide, semaglutide and tirzepatide likewise reported no clear increase in severe events such as pancreatitis [8].

What is known about the biology

Tirzepatide binds and activates both the GIP and the GLP-1 receptor [1]. Activation of GLP-1 and GIP receptors leads to effects in multiple tissues beyond glucose control, through direct actions on tissues that express incretin receptors and through indirect neuronal and endocrine pathways [2].

How, or whether, that receptor activation leads to an inflamed pancreas has not been established. Pooled trial results do not show a statistically significant excess of pancreatitis with tirzepatide [4] or with GLP-1 receptor agonists generally [6][7].

Gallstones and biliary disease

Section 5.8 of the Mounjaro label reports acute gallbladder disease, meaning cholelithiasis, biliary colic and cholecystectomy, in 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients in the adult placebo-controlled trials, and says that suspected cholelithiasis warrants gallbladder studies and clinical follow-up [1].

Against placebo or basal insulin, tirzepatide was associated with more events in a combined gallbladder-or-biliary outcome, with a risk ratio of 1.97 (95% CI 1.14 to 3.42); the individual outcomes of cholelithiasis, cholecystitis and biliary disease were not each statistically significant [4]. The 2025 meta-analysis of 99,599 patients across GLP-1 receptor agonists and tirzepatide found gallbladder disorders 26% more frequent than with controls [7].

Gallstones are the most common cause of acute pancreatitis [3], and the authors of the 2023 meta-analysis wrote that the higher composite gallbladder-or-biliary risk warrants further attention from physicians in practice [4]. Whether gallstones account for any pancreatitis in people taking Mounjaro has not been established.

Amylase and lipase on Mounjaro

The label reports mean increases from baseline in serum pancreatic amylase of 33% to 38% and in lipase of 31% to 42% with Mounjaro, and states that the clinical significance of elevations in lipase or amylase is unknown in the absence of other signs and symptoms of pancreatitis [1].

The baseline these patients already carry

The population prescribed Mounjaro already has a higher pancreatic risk before any drug exposure. In a US health-claims cohort of 337,067 adults with type 2 diabetes matched by age and sex to 337,067 adults without diabetes, the diabetes group had 2.83 times the risk of acute pancreatitis (95% CI 2.61 to 3.06) and 1.91 times the risk of biliary disease; the excess was largest in people younger than 45 (incidence rate ratio 5.26) [5]. Mounjaro is indicated for type 2 diabetes in adults and in children 10 years and older, and to reduce major cardiovascular events in adults with type 2 diabetes at high risk [1].

Recognizing it, and how it is diagnosed

The label's symptom description is the practical starting point: persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting [1]. In the American College of Gastroenterology guideline, the diagnosis of acute pancreatitis is most often established by clinical symptoms plus laboratory testing, and contrast-enhanced CT or MRI is reserved for patients whose diagnosis is unclear or who fail to improve clinically [9].

How tirzepatide compares with other incretin drugs

Other incretin-based drugs have been studied for pancreatitis too. In LEADER, which randomized 9,340 patients with type 2 diabetes and high cardiovascular risk, the incidence of pancreatitis was nonsignificantly lower in the liraglutide group than in the placebo group [10]. In TECOS, which randomized 14,671 patients to sitagliptin or placebo, there were no significant between-group differences in rates of acute pancreatitis (P=0.07) [11].

The comparison people most want is tirzepatide against semaglutide. The 2023 meta-analysis pooled placebo, basal insulin and GLP-1 receptor agonist comparators into a single control group, so its result does not separate tirzepatide from semaglutide or dulaglutide specifically [4]. Across the whole class plus tirzepatide, the 2025 meta-analysis of 99,599 patients found no difference in pancreatitis versus controls [7].